177lu-psma-617
novartis,bayer
['crpc', 'pcsm', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'ralu']
 the question ralu set out to ask is whether it is safe to sequence two radionuclide therapies, an alpha and a beta emitter, in patients with #mcrpc. - | #pcsm #gu23 
Oncology news and insights from leading researchers and cancer centers.